Policy / Pricing What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge pharminent May 11, 2026
Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026
Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
Commercial Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth pharminent April 30, 2026
Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial pharminent April 30, 2026
Commercial Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ pharminent April 29, 2026
Clinical Data Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3 pharminent April 28, 2026
Market Access CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage pharminent April 23, 2026
Pipeline Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ pharminent April 23, 2026
Market Access Medicare weight loss drug pilot on ice as insurers decline to contribute pharminent April 22, 2026
Policy / Pricing Medicare obesity drug pilot extended after insurer pushback pharminent April 22, 2026
Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market pharminent April 20, 2026
Commercial Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool pharminent April 17, 2026
Commercial Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch pharminent April 17, 2026
Clinical Data Novo may have muscle advantage over Lilly in weight-loss race: preprint pharminent April 17, 2026
Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes pharminent April 16, 2026
Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials pharminent April 16, 2026
Clinical Data Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns pharminent April 16, 2026
M&A / Deals Obesity’s explosive growth continues as Q1 deals exceed total 2025 value pharminent April 16, 2026
Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data pharminent April 15, 2026
Manufacturing Lilly investing billions to prepare for overseas oral GLP-1 launches pharminent April 14, 2026
Other 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease pharminent April 13, 2026
Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch pharminent April 10, 2026
M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation pharminent April 10, 2026
Commercial Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk pharminent April 9, 2026
Commercial Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences pharminent April 2, 2026
Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity pharminent April 2, 2026
Regulatory Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry pharminent April 2, 2026
M&A / Deals Biocytogen and Sihuan partner to advance new therapeutics for weight loss pharminent April 2, 2026
